AIDS MALIGNANCY CONSORTIUM

这份加入恶性艾滋病协会的申请是由Joseph a . Sparano博士代表Montefiore医疗中心（包括Moses分部和Weiler分部）和其他四个机构组成的协会提交的，这些机构包括Jacobi医疗中心、北布朗克斯中央区医院、布朗克斯黎巴嫩医院和长岛犹太医疗中心。仅在Montefiore医疗中心（MMC），在过去8年里，在斯帕拉诺博士的指导下，就有111名hiv相关恶性肿瘤患者参加了临床试验。布朗克斯区的艾滋病毒感染率是全国最高的，该联盟的六家医院中有五家为布朗克斯区提供服务。在布朗克斯的120万居民中，估计约有30,000人（16,000人）有意或无意地（14,000人）感染了艾滋病毒。这个社区不仅有以医院为基础的艾滋病毒专科护理诊所，还有隶属于MMC或布朗克斯黎巴嫩医院（BLH）的30多个社区诊所。BLH也有一个积极的社区外展计划。大约5900名患者接受联合机构提供的初级艾滋病毒护理。此外，在联合机构中，估计每年约有110名新诊断为hiv相关和aids相关癌症的患者，其中包括46名系统性淋巴瘤患者，14名原发性中枢神经系统淋巴瘤患者和50名卡波西肉瘤患者。MMC在癌症和艾滋病研究的临床试验方面有着丰富的经验。它是阿尔伯特·爱因斯坦医学院（AECOM）的大学医院，因此是nci指定的AECOM综合癌症中心的临床部门。每年都有超过100个临床协议生效，超过400名患者被纳入临床试验，其中约55%的临床试验参与者是非裔美国人或拉丁美洲人。MMC也是东方肿瘤合作组织的成员。在1997年ECOG对MMC临床试验表现和数据管理的最后一次审核中，MMC被ECOG评为优秀至优秀。纽约州指定的艾滋病中心设在MMC和BLH， MMC、BLH和Jacobi医疗中心参加了CPCRA。因此，MMC及其合作伙伴非常适合成为AMC的富有成效的成员，因为其庞大的患者基础，在癌症临床试验方面的丰富经验，以及其首席研究员所展示的科学领导地位。

This application for membership in the AIDS Malignancy Consortium is submitted by Dr. Joseph A. Sparano on behalf of Montefiore Medical Center (including the Moses Division and Weiler Division) and a consortium of four other institutions, including Jacobi Medical Center, North Central Bronx Hospital, Bronx Lebanon Hospital, and Long Island Jewish Medical Center. At Montefiore Medical Center (MMC) alone, 111 patients with HIV-associated malignancies have been enrolled on clinical trials under Dr. Sparano s direction over the past 8 years. The prevalence of HIV infection in the Bronx, the community served by five of the six hospitals in this consortium, is among the highest in the nation. Of the 1.2 million residents of the Bronx, it is estimated that about 30,000 are knowingly (16,000) or unknowingly (14,000) HIV- infected. This community is served not only by hospital-based HIV specialty care clinics, but also by over 30 community-based clinics affiliated with MMC or Bronx Lebanon Hospital (BLH). BLH also has an active community outreach program. Approximately 5900 patients receive primary HIV care by the consortium institutions. Moreover, among consortium institutions, it is estimated that each year there are approximately 110 patients newly diagnosed with HIV-associated and AIDS-associated cancers each year, including 46 patients wit systemic lymphoma, 14 patients with primary CNS lymphoma, and 50 patients with Kaposi s sarcoma. MMC has extensive experience in clinical trials in cancer and AIDS research. It is the University Hospital of the Albert Einstein College of Medicine (AECOM), and as such is the clinical arm of the NCI-designated Comprehensive Cancer Center at AECOM. Each year, over 100 clinical protocols are active, over 400 patients are enrolled on clinical trials, and about 55 percent of those enrolled on clinical trials are either African- American or Latino. MMC is also a member of the Eastern Cooperative Oncology Group. At ECOG s last audit of MMC s clinical trials performance and data management in 1997, MMC was rated as excellent to outstanding by ECOG. New York State- designated AIDS centers are based at MMC and BLH, and MMC, BLH, and Jacobi Medical Center participate in the CPCRA. MMC and its partners are therefore ideally suited to become productive members of AMC because of its large patient base, its considerable experience in cancer clinical trials, and the scientific leadership that has been demonstrated by its principal investigator.